ABH Healthcare Share Price & Stock Analysis

Quick Answers

What is the ABH Healthcare share price today? ABH Healthcare is currently listed and trading. Check our charts for the latest listing performance.

Is ABH Healthcare a good stock to buy? Review our AI forensic scores and fundamental analysis for ABH Healthcare to understand the underlying financial health.

Key Stock Information

ViewIPO AI Analysis Score

The ABH Healthcare Stock scored 58/100 (High Risk) in our deep analysis.

Frequently Asked Questions

What is the primary business of ABH Healthcare Ltd?

ABH Healthcare Ltd operates the 150-bed tertiary care Anil Baghi Hospital in Ferozepur, Punjab, offering services across 25 medical specialties.

What are the opening and closing dates for the ABH Healthcare IPO?

The IPO opens on August 24, 2026, and closes on August 26, 2026.

What is the price band and minimum investment required for the ABH Healthcare IPO?

The price range is ₹96 to ₹102 per share with a lot size of 1,200 shares, requiring a minimum investment of ₹2,30,400 at the upper price band.

What is the total issue size of the ABH Healthcare IPO?

The total issue size is ₹34.98 Crore.

What are the key financial risks for ABH Healthcare Ltd?

Major risks include 100% revenue dependency on a single hospital in Ferozepur, a high debt-to-equity ratio of 3.20, heavy supplier concentration (83.85% from top 5 suppliers), and recurring negative cash flows from investing activities.

How has ABH Healthcare Ltd performed financially over the last three fiscal years?

Revenue from operations grew from ₹41.38 Crore in FY24 to ₹49.27 Crore in FY25 and ₹52.51 Crore in FY26, while profit after tax stood at ₹5.64 Crore in FY26.

View IPO
View IPO
Home›India›ABH Healthcare ()
ABH Healthcare Logo

ABH HealthcareNSE SME / BSE SME:

Analyzed by ViewIPO Financial Research Team
HealthcareIndiaFiled 2026-08-24Listed 2026-09-01Size Pending Data
Lot Size 1200
Listing Price ₹102
Listing Return
₹-3.00 (-2.94%)
Live Subscription
1.41x Total
Check Allotment
Status Link

Is ABH Healthcare a Good Stock? Quick Verdict

ABH Healthcare IPO scored 58/100 (High Risk) in our deep analysis. The strongest pillar is Financial at 65/100, while Competition is the primary concern at 45/100. ABH Healthcare Ltd shows steady revenue expansion and accredited clinical operations, but carries high geographic risk, heavy debt leverage, and significant vendor concentration.

Stock Score
58/100
High Risk

Quick Verdict

EBITDA expanded significantly from ₹6.89 Cr in FY24 to ₹14.44 Cr in FY26.
Empaneled with over 30 private and public health insurance companies, TPAs, and government schemes like Ayushman Bharat and ECHS.
100% operational and revenue concentration in a single hospital location in Ferozepur, Punjab.
High debt-to-equity ratio standing at 3.20 in FY26 with total borrowings of ₹52.33 Cr.
High vendor concentration, with the top 5 suppliers accounting for 83.85% of total purchases in FY26 without long-term contracts.

Company Snapshot

Revenue (TTM)
₹52.51Cr↑ 6.58% YoY
Profitability
PositiveNet Income ₹5.64Cr
Gross Margin
— 
Market Cap
—Pending Data
Issue Size
— 
Industry
Healthcare 
P/E Ratio
—Pending Data
Debt to Equity
3.2xLeverage

Risk Breakdown

Governance
65
Moderate
Financial
65
Moderate
Valuation
50
Expensive
Competition
45
Expensive
Dilution
60
Moderate
Promoter / Mgmt
60
Moderate

AI Summary

ABH Healthcare Ltd operates the 150-bed tertiary care Anil Baghi Hospital in Ferozepur, Punjab, providing multi-specialty healthcare services across 25 clinical fields. Incorporated in 2021 to acquire the long-standing hospital business, ABH Healthcare Ltd expanded its operating revenue to ₹52.51 Crore with an EBITDA of ₹14.44 Crore in FY26. However, ABH Healthcare Ltd faces key risk factors including total operational concentration in a single facility, high debt-to-equity leverage of 3.20, and significant reliance on government schemes and top suppliers.

Overall Verdict: ABH Healthcare Ltd shows steady revenue expansion and accredited clinical operations, but carries high geographic risk, heavy debt leverage, and significant vendor concentration.

Key Highlights

  • •Operates the 150-bed Anil Baghi Hospital established in 1985 and acquired by the company in March 2022.
  • •Provides tertiary healthcare services across 25 specialties including cardiology, neurosurgery, gastroenterology, and nephrology.
  • •NABH accredited and awarded NABH Digital Standards accreditation in FY25.
  • •Employs 37 doctors and 101 nurses as of June 30, 2026, with over 30% of doctors associated for over 5 years.
  • •Government schemes and PSUs contributed 52.40% of standalone revenue from operations in FY26.
  • •EBITDA increased from ₹6.89 Crore in FY24 to ₹14.44 Crore in FY26.

Financial Performance

Revenue (Annual)

↑ +6.6% YoY

INR in Crores

Net Income (Annual)

↑ +5.4% YoY

INR in Crores

EBITDA vs PAT

EBITDA YoY

INR in Crores

EBITDA
PAT

Listing Timeline

IPO Opens2026-08-24
IPO Closes2026-08-27
Basis of Allotment2026-08-28
Refunds & Demat2026-08-29
Listing Date2026-09-01

Valuation Analysis

Issue Price₹102
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

Stock DNA

Growth
55
Governance
65
Profitability
65
Valuation
50
Competition
45
Execution
60

Pros vs Cons

Pros

  • Experienced clinical leadership team led by Dr. Kamal Baghi with nearly four decades of healthcare expertise.
  • Diversified clinical revenue stream across 25 medical specialties.
  • Strong EBITDA growth from ₹6.89 Cr in FY24 to ₹14.44 Cr in FY26.
  • Empaneled with over 30 insurance companies and major public sector health schemes.

Cons

  • 100% operational and revenue concentration in a single hospital in Ferozepur, Punjab.
  • High debt burden with a consolidated debt-to-equity ratio of 3.20 and ₹52.33 Cr total borrowings as of June 2026.
  • Heavy vendor concentration with the top 5 suppliers accounting for 83.85% of total purchases in FY26.
  • Limited operating history as a corporate entity following business acquisition in March 2022.
  • Sustained negative cash flows from investing activities across FY24, FY25, and FY26.

Financial Health

Revenue Growth
12.6% CAGR (FY24-FY26) (Moderate)
Debt Level
D/E 3.20 (FY26), Total Debt ₹52.33 Cr (Weak)
Cash & Equivalents
Negative investing cash flow (-₹9.14 Cr in FY26) (Weak)

Institutional Signals

Anchor Investors
Undisclosed
VC Backing Tier
None
Strategic Partners
Moderate

ABH Healthcare IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

ABH Healthcare Stock — Frequently Asked Questions

Related Stock Reports

R K Fashion

R K Fashion

RKFAL
55/100
View Report
R

RKFashion Accessories

BSE SME
0/100
View Report
Acme India

Acme India

ACMERAIL
56/100
View Report
Acme India Industries

Acme India Industries

ACMERAIL
54/100
View Report
Paramount Syntex

Paramount Syntex

PARASYNTEX
57/100
View Report
View All Active & Upcoming Stocks & IPOs View Stock & IPO Calendar

Market Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another stock or IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about ABH Healthcare

What is the expected listing price of ABH Healthcare?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for ABH Healthcare on our Live GMP Tracker.